Case report| Volume 42, 102058, July 2020

Drug reaction with eosinophilia and systemic symptoms after ocrelizumab therapy


      • Drug reaction with eosinophilia and systemic symptoms (DRESS) occurs rarely with biological drugs.
      • DRESS-related symptoms include fever, cutaneous eruption, internal organ involvement, and hematologic abnormalities.
      • If DRESS-like symptoms occur, prompt withdrawal of the suspected medication is indicated.
      • Antihistamine treatment is recommended and administration of oral corticosteroids may be necessary.


      We report here on a young woman with multiple sclerosis, who developed a condition with eosinophilia and swelling of limbs seven weeks after initiation of ocrelizumab treatment. We consider her drug reaction to be compatible with a drug reaction with eosinophilia and systemic symptoms (DRESS), also called drug-induced hypersensitivity syndrome. She was treated with antihistamine and corticosteroid treatments, and recovered fully within three months of symptom onset. Ocrelizumab was not re-initiated. We are not aware of other DRESS-like cases related to ocrelizumab treatment.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. European Medicines Agency (2018) - European public assessment report (EPAR) - Ocrevus. Ema.

        • Kuruvilla M.
        • Khan D.A.
        Eosinophilic drug allergy.
        Clin. Rev. Allergy Immunol. 2016; 50: 228-239
        • Lu J.
        • Thuraisingam T.
        • Chergui M.
        • Nguyen K.
        Nivolumab-associated DRESS syndrome: a case report.
        JAAD Case Rep. 2019; 5: 216-218
        • Rauer S.
        • Stork L.
        • Urbach H.
        • Stathi A.
        • Marx A.
        • Suss P.
        • Prinz M.
        • Bruck W.
        • Metz I.
        Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy.
        Neurology. 2018; 91: E359-E363
        • White J.M.L.
        • Smith C.H.
        • Robson A.
        • Ash G.
        • Barker J.
        DRESS syndrome caused by efalizumab.
        Clin. Exp. Dermatol. 2008; 33: 50-52